Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Cerecor divests non-core neurology pipeline assets to Alto Neuroscience, ES » 07:33
06/23/21
06/23
07:33
06/23/21
07:33
CERC

Cerecor

$3.50 /

-0.085 (-2.37%)

Cerecor announces that it…

Cerecor announces that it has divested its non-core neurology pipeline assets to Alto Neuroscience and ES Therapeutics, respectively. The company previously disclosed its intentions to explore strategic alternatives for these neurology pipeline assets, which are non-core to the company's business, and focus on developing innovative therapies in areas of high unmet need within the fields of immunology, immuno-oncology, and rare genetic disorders. As part of the divestitures, Cerecor will receive undisclosed initial payments and is eligible to receive additional payments upon achievement of specified development, regulatory and sales-based milestones. Cerecor is also entitled to royalty payments based on net sales of CERC-301.

ShowHide Related Items >><<
CERC Cerecor
$3.50 /

-0.085 (-2.37%)

CERC Cerecor
$3.50 /

-0.085 (-2.37%)

06/04/21 Cantor Fitzgerald
Cerecor initiated with an Overweight at Cantor Fitzgerald
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
CERC Cerecor
$3.50 /

-0.085 (-2.37%)

  • 08
    Jan
CERC Cerecor
$3.50 /

-0.085 (-2.37%)

Hot Stocks
Cerecor licenses immune checkpoint program from Sanford Burnham Prebys » 07:33
06/23/21
06/23
07:33
06/23/21
07:33
CERC

Cerecor

$3.50 /

-0.085 (-2.37%)

Cerecor announced that it…

Cerecor announced that it has entered into an exclusive license agreement with Sanford Burnham Prebys for the worldwide development and commercialization of an immune checkpoint program. The acquisition further enhances the company's development pipeline of novel biologics that address immunology and immuno-oncology targets. Under the terms of the agreement, Sanford Burnham Prebys will receive an up-front payment from Cerecor and is also eligible to receive additional payments based on achievement of development, regulatory and commercial milestones, sales-based royalties and a share of sublicensing income.

ShowHide Related Items >><<
CERC Cerecor
$3.50 /

-0.085 (-2.37%)

CERC Cerecor
$3.50 /

-0.085 (-2.37%)

06/04/21 Cantor Fitzgerald
Cerecor initiated with an Overweight at Cantor Fitzgerald
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
CERC Cerecor
$3.50 /

-0.085 (-2.37%)

  • 08
    Jan
CERC Cerecor
$3.50 /

-0.085 (-2.37%)

Hot Stocks
Cerecor enters $35M debt financing agreement with Horizon Technology » 07:24
06/07/21
06/07
07:24
06/07/21
07:24
CERC

Cerecor

$2.91 /

+0.185 (+6.79%)

, HRZN

Horizon Technology

$16.93 /

+0.16 (+0.95%)

Cerecor Inc. (CERC)…

Cerecor Inc. (CERC) announced that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) to provide up to $35.0 million in term loans. $20 million of the $35 million loan was funded upon closing. The remaining $15 million may be funded upon Cerecor achieving certain predetermined milestones. Each advance of the loan will be repaid in 42 monthly payments consisting of 18 monthly payments of interest only, followed by 24 monthly payments of principal and accrued interest, and will be payable monthly in arrears. The interest-only period may be extended to 24 months contingent upon Cerecor achieving certain milestones. In connection with the financing, Cerecor issued Horizon warrants to purchase up to 403,844 of its common shares at an exercise price of $2.60 per share. Proceeds will be used to support the ongoing clinical development of key investigational product candidates within its pipeline and for general working capital purposes.

ShowHide Related Items >><<
HRZN Horizon Technology
$16.93 /

+0.16 (+0.95%)

CERC Cerecor
$2.91 /

+0.185 (+6.79%)

CERC Cerecor
$2.91 /

+0.185 (+6.79%)

06/04/21 Cantor Fitzgerald
Cerecor initiated with an Overweight at Cantor Fitzgerald
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
HRZN Horizon Technology
$16.93 /

+0.16 (+0.95%)

04/29/21 B. Riley
Horizon Technology price target raised to $14.50 from $11.50 at B. Riley
01/14/21 Compass Point
Horizon Technology downgraded to Sell from Neutral at Compass Point
11/19/20 JMP Securities
TriplePoint Venture resumed with an Outperform at JMP Securities
09/23/20
Fly Intel: Top five analyst initiations
HRZN Horizon Technology
$16.93 /

+0.16 (+0.95%)

CERC Cerecor
$2.91 /

+0.185 (+6.79%)

  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$2.91 /

+0.185 (+6.79%)

Initiation
Cerecor initiated with an Overweight at Cantor Fitzgerald » 06:49
06/04/21
06/04
06:49
06/04/21
06:49
CERC

Cerecor

$2.72 /

-0.09 (-3.20%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen initiated coverage of Cerecor with an Overweight rating and $7 price target. The peak sales potential of Cerecor's pipeline of rare and orphan diseases is underappreciated, Chen tells investors in a research note, adding that she believes upwards earnings revision, driven by pipeline advancements, should move the stock higher,

ShowHide Related Items >><<
CERC Cerecor
$2.72 /

-0.09 (-3.20%)

CERC Cerecor
$2.72 /

-0.09 (-3.20%)

04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
CERC Cerecor
$2.72 /

-0.09 (-3.20%)

  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$2.72 /

-0.09 (-3.20%)

Conference/Events
Oppenheimer to hold a virtual summit » 09:38
05/21/21
05/21
09:38
05/21/21
09:38
BMRN

BioMarin

$79.16 /

+2.83 (+3.71%)

, CATB

Catabasis Pharmaceuticals

$1.95 /

+0.07 (+3.72%)

, CERC

Cerecor

$2.70 /

+0.11 (+4.25%)

, CLRB

Cellectar Biosciences

$1.46 /

-0.02 (-1.35%)

, CMMB

Chemomab Therapeutics

$19.13 /

+0.28 (+1.49%)

, CRBP

Corbus Pharmaceuticals

$1.71 /

+0.095 (+5.88%)

, DCTH

Delcath Systems

$10.46 /

+ (+0.00%)

, ELOX

Eloxx Pharmaceuticals

$1.59 /

+0.12 (+8.16%)

, MGTX

MeiraGTx

$13.10 /

+0.35 (+2.75%)

, MITO

Stealth Biotherapeutics

$1.29 /

-0.035 (-2.64%)

, PRAX

Praxis Precision Medicines

$20.00 /

+0.21 (+1.06%)

, SBBP

Strongbridge Biopharma

$2.33 /

+0.03 (+1.30%)

, SLNO

Soleno Therapeutics

$1.01 /

+0.0058 (+0.58%)

, SVRA

Savara

$1.60 /

-0.05 (-3.03%)

, TARA

Protara Therapeutics

$9.40 /

+0.24 (+2.62%)

Rare & Orphan Disease…

Rare & Orphan Disease Virtual Summit to be held on May 21.

ShowHide Related Items >><<
TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

SVRA Savara
$1.60 /

-0.05 (-3.03%)

SLNO Soleno Therapeutics
$1.01 /

+0.0058 (+0.58%)

SBBP Strongbridge Biopharma
$2.33 /

+0.03 (+1.30%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

MITO Stealth Biotherapeutics
$1.29 /

-0.035 (-2.64%)

MGTX MeiraGTx
$13.10 /

+0.35 (+2.75%)

ELOX Eloxx Pharmaceuticals
$1.59 /

+0.12 (+8.16%)

DCTH Delcath Systems
$10.46 /

+ (+0.00%)

CRBP Corbus Pharmaceuticals
$1.71 /

+0.095 (+5.88%)

CMMB Chemomab Therapeutics
$19.13 /

+0.28 (+1.49%)

CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

CERC Cerecor
$2.70 /

+0.11 (+4.25%)

CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

04/30/21 Wedbush
BioMarin's Q1 revenue was better than expected, says Wedbush
04/26/21 Credit Suisse
BioMarin assumed with an Outperform at Credit Suisse
03/04/21 Guggenheim
BioMarin assumed at Buy from Neutral at Guggenheim
03/01/21 Evercore ISI
BioMarin upgraded to Outperform from In Line at Evercore ISI
CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

05/12/21 Ladenburg
Ladenburg starts Catabasis Pharmaceuticals at Buy with $6 price target
05/12/21 Ladenburg
Catabasis Pharmaceuticals initiated with a Buy at Ladenburg
03/11/21 Oppenheimer
Catabasis Pharmaceuticals upgraded to Outperform at Oppenheimer
03/11/21 Oppenheimer
Catabasis upgraded to Outperform from Perform at Oppenheimer
CERC Cerecor
$2.70 /

+0.11 (+4.25%)

04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

04/27/21 Roth Capital
Cellectar strengthens IP estate as CLR 131 trial progresses, says Roth Capital
07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
CMMB Chemomab Therapeutics
$19.13 /

+0.28 (+1.49%)

05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CRBP Corbus Pharmaceuticals
$1.71 /

+0.095 (+5.88%)

10/08/20 H.C. Wainwright
Corbus Pharmaceuticals price target lowered to $3 from $6 at H.C. Wainwright
10/06/20 Roth Capital
Corbus Pharmaceuticals price target lowered to $1.22 from $3 at Roth Capital
09/08/20 Jefferies
Corbus Pharmaceuticals downgraded to Hold from Buy at Jefferies
09/08/20 Oppenheimer
Corbus Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
DCTH Delcath Systems
$10.46 /

+ (+0.00%)

04/06/21 Roth Capital
Delcath Systems price target raised to $25 from $20 at Roth Capital
03/09/21 Canaccord
Delcath Systems initiated with a Buy, $24 target at Canaccord
03/09/21 Canaccord
Delcath Systems initiated with a Buy at Canaccord
01/05/21
BTIG starts Delcath Systems at Buy, sees 'compelling' FOCUS trial data
ELOX Eloxx Pharmaceuticals
$1.59 /

+0.12 (+8.16%)

05/19/21 Piper Sandler
Eloxx Pharmaceuticals price target lowered to $4 from $6 at Piper Sandler
04/01/21 Piper Sandler
Eloxx Pharmaceuticals acquires Zikani in all-stock deal, says Piper Sandler
06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
MGTX MeiraGTx
$13.10 /

+0.35 (+2.75%)

04/28/21 Piper Sandler
MeiraGTx should be bought into the $40 range, says Piper Sandler
02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
MITO Stealth Biotherapeutics
$1.29 /

-0.035 (-2.64%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
SBBP Strongbridge Biopharma
$2.33 /

+0.03 (+1.30%)

09/08/20 JMP Securities
Weakness in Strongbridge Biopharma 'a buying opportunity,' says JMP Securities
SLNO Soleno Therapeutics
$1.01 /

+0.0058 (+0.58%)

09/29/20 Guggenheim
Soleno Therapeutics initiated with a Buy at Guggenheim
SVRA Savara
$1.60 /

-0.05 (-3.03%)

04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
03/16/21
Fly Intel: Top five analyst initiations
03/16/21 Piper Sandler
Savara initiated with an Overweight at Piper Sandler
03/15/21 Oppenheimer
Savara initiated with an Outperform at Oppenheimer
TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

SVRA Savara
$1.60 /

-0.05 (-3.03%)

SLNO Soleno Therapeutics
$1.01 /

+0.0058 (+0.58%)

SBBP Strongbridge Biopharma
$2.33 /

+0.03 (+1.30%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

MITO Stealth Biotherapeutics
$1.29 /

-0.035 (-2.64%)

MGTX MeiraGTx
$13.10 /

+0.35 (+2.75%)

DCTH Delcath Systems
$10.46 /

+ (+0.00%)

CRBP Corbus Pharmaceuticals
$1.71 /

+0.095 (+5.88%)

CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

CERC Cerecor
$2.70 /

+0.11 (+4.25%)

CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

  • 14
    May
  • 14
    May
  • 11
    Mar
  • 08
    Jan
  • 23
    Dec
  • 09
    Dec
  • 19
    Nov
  • 16
    Oct
  • 22
    Sep
  • 17
    Sep
  • 24
    Jun
  • 09
    Jun
BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

DCTH Delcath Systems
$10.46 /

+ (+0.00%)

CMMB Chemomab Therapeutics
$19.13 /

+0.28 (+1.49%)

CERC Cerecor
$2.70 /

+0.11 (+4.25%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

SVRA Savara
$1.60 /

-0.05 (-3.03%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

Earnings
Cerecor reports Q1 EPS (32c), consensus (19c) » 07:13
05/13/21
05/13
07:13
05/13/21
07:13
CERC

Cerecor

$2.35 /

-0.25 (-9.62%)

Reports Q1 revenue…

Reports Q1 revenue $473,000, consensus $3.78M. "It has been a productive start to the year," said Mike Cola, Chief Executive Officer of Cerecor. "Over the course of 2021, we anticipate multiple data readouts, including CERC-007 in multiple myeloma and adult onset Still's disease and CERC-006 in complex lymphatic malformations, that will demonstrate significant progress in developing treatments for immunology, oncology, and rare genetic disorders."

ShowHide Related Items >><<
CERC Cerecor
$2.35 /

-0.25 (-9.62%)

CERC Cerecor
$2.35 /

-0.25 (-9.62%)

04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$2.35 /

-0.25 (-9.62%)

Hot Stocks
Cerecor announces FDA granted fast track designation for CERC-002 for COVID-19 » 07:15
05/11/21
05/11
07:15
05/11/21
07:15
CERC

Cerecor

$2.55 /

-0.15 (-5.56%)

Cerecor announced that…

Cerecor announced that the Food and Drug Administration has granted Fast Track designation to CERC-002 for treatment of hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT. Fast Track designation is granted to drugs being developed for the treatment of serious or life-threatening diseases or conditions where there is an unmet medical need. Sponsors of drugs that receive Fast Track designation have the opportunity for more frequent interactions with the FDA review team throughout the development program. Under Fast Track designation, a Biologic License Application for CERC-002 is eligible for both rolling submission and priority review.

ShowHide Related Items >><<
CERC Cerecor
$2.55 /

-0.15 (-5.56%)

CERC Cerecor
$2.55 /

-0.15 (-5.56%)

04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$2.55 /

-0.15 (-5.56%)

Hot Stocks
Cerecor doses first patient in Phase 1b proof-of-concept trial of CERC-007 » 07:20
05/05/21
05/05
07:20
05/05/21
07:20
CERC

Cerecor

$2.92 /

-0.175 (-5.66%)

Cerecor announced that it…

Cerecor announced that it has dosed its first patient in a Phase 1b open-label dose-escalation clinical trial of CERC-007 in patients with adult onset Still's disease, or AOSD. The Phase 1b clinical trial is a global multi-center, open-label trial of CERC-007 that will enroll approximately 12 subjects with active adult onset Still's disease. The primary objective of the study will be to determine the safety and tolerability of CERC-007 in AOSD patients. Key secondary endpoints include assessing pharmacokinetic profile of CERC-007 and determining the effect of CERC-007 on systemic clinical manifestations and systemic markers of inflammation in subjects with AOSD. The company anticipates initial data to be reported in the third quarter of 2021.

ShowHide Related Items >><<
CERC Cerecor
$2.92 /

-0.175 (-5.66%)

CERC Cerecor
$2.92 /

-0.175 (-5.66%)

04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$2.92 /

-0.175 (-5.66%)

Over a quarter ago
Upgrade
Cerecor upgraded to Buy from Hold at Maxim » 07:46
04/21/21
04/21
07:46
04/21/21
07:46
CERC

Cerecor

$2.35 /

-0.04 (-1.67%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy upgraded Cerecor to Buy from Hold with a $7 price target. The company continues to make significant progress with CERC-002 as data emerged in early March and was then followed by a licensing agreement with Kyowa Kiring that continues to support the potential of this antibody in inflammatory-related conditions - most advanced of which is COVRD-related ARDS, the analyst tells investors in a research note. McCarthy further cites Cerecor other key asset - CERC-007 targeting IL-18 and initially being developed for multiple myeloma - stating that it should stand out as a differentiating factor in a "crowded space".

ShowHide Related Items >><<
CERC Cerecor
$2.35 /

-0.04 (-1.67%)

CERC Cerecor
$2.35 /

-0.04 (-1.67%)

04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$2.35 /

-0.04 (-1.67%)

Upgrade
Cerecor upgraded to Buy from Hold at Maxim » 07:40
04/21/21
04/21
07:40
04/21/21
07:40
CERC

Cerecor

$2.35 /

-0.04 (-1.67%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy upgraded Cerecor to Buy from Hold with a $7 price target.

ShowHide Related Items >><<
CERC Cerecor
$2.35 /

-0.04 (-1.67%)

CERC Cerecor
$2.35 /

-0.04 (-1.67%)

04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$2.35 /

-0.04 (-1.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.